This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Georgiadou SP, Lewis RE, Best L, Torres HA, Champlin RE . The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary profylaxis. Bone Marrow Transplant 2013; 48: 141–143.
Vehreschild JJ, Sieniawski M, Reuter S, Arenz D, Reichert D, Maertens J et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from multinational case registry. Int J Antimicrob Agents 2009; 34: 446–450.
Zhang P, Song A, Wang S, Feng S, Qiu L, Han M . Hematopoietic SCT in patients with history of invasive fungal infection. Bone Marrow Transplant 2009; 43: 533–537.
Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the EGIL3 -2009 update. Bone Marrow Transplantation 2011; 46: 709–718.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Salmenniemi, U., Remes, K. & Itälä-Remes, M. Outcome of allogeneic SCT in patients with pre-transplant invasive fungal infection. Bone Marrow Transplant 48, 1262–1263 (2013). https://doi.org/10.1038/bmt.2013.45
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2013.45